TORC - resTORbio: Strong Results In Phase 2 Makes This Worth A Look

resTORbio, Inc. (TORC) is a clinical-stage, specialty biopharmaceutical company. They are developing medicines that target the biology of aging to prevent or treat aging-related diseases. The company's lead product candidate, RTB101, is an orally administered, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1). Preclinical studies have shown that TORC1 inhibition benefits multiple aging-related conditions, including immunosenescence, which is the decline of a body’s immune system during aging.

Catalyst

resTORbio stock has been rallying around the middle of its 52-week range of $6.21 - $16.66, since 7/23/2019, when the company announced